Book of Abstracts - Ruhr-Universität Bochum

P-70
ISBOMC `10 5.7 – 9.7. 2010 Ruhr-Universität Bochum
Synthesis, Characterization and Antitumor Screening of some
Di- and Triorganotin(IV) Complexes of 2,9-Dimethyl-1,10-phenanthrolin
Mojdeh Safari,* a Mohammad Yousefi, a Maryam Bikhof, a Amir Amanzadeh, b
Mohammad Ali Shokrgozar, b and Fatemeh Tavakolinia a
a Azad University, Shahre-rey branch, Tehran, Iran
b Pasteur Institute, Tehran, Iran. E-mail: msafari96@yahoo.com
Malignancy is the result from a multiple process by accumulation of mutations and other genetic
alteration. 1 Searches for non-platin metal-based antitumor drugs have attracted considerate interest.
Diorganotin(IV) complexes are potential antitumor agents mainly active against P388 lymphocytic
leukemia and other tumors. 2-4 Recent studies have shown very promising in vitro antitumor properties
of organotin compounds against a wide panel of tumor cell lines of human origin. 5-11 In some cases,
organotin(IV) derivatives have also shown acceptable antiproliferative in vivo activity as new
chemotherapy agents. 12-17 In this context ,we decided to study the cytotoxic activity of 2,9-Dimethyl-
1,10phenanthrolin tin(IV) derivatives, in order to observe the influence of the substituents attached to
the central Sn atom on the final anticancer activity of the organotin(IV) complexes. In the present
research the new complexes of organotin were obtained by reacting R2SnCl2 and Ŕ3SnCl (where R=
Methyl, Butyl, Benzyl and Ŕ= Phenyl) with 2,9-Dimethyl-1,10phenanthrolin. These complexes have
been characterized by FT-IR and 1 H, 13 C, 119 Sn NMR and Mass spectroscopy. The cytotoxic activity of
the studied compounds has been investigated against K562 cell line and the IC50 values have been
determined.
References
1. P. Blume-Jensen, T. Hunter, Nature, 2001, 411, 355–357.
2. A.J. Crowe: Antitumor activity of tin compounds in Metal Compounds in Cancer Therapy; S.P.
Fricker, Ed., Chapman & Hall: London, GB, 1994, pp. 147–179.
3. A.J. Crowe, P.J. Smith, C.J. Cardin, H.E. Parge, F.E. Smith, Cancer Lett., 1984, 24, 45–48.
4. (a) A.K. Saxena, F. Huber, Coord. Chem. Rev., 1989, 95, 109–123. (b) M. Gielen (Ed.), Tin-Based
Anti-Tumor Drugs, Springer-Verlag, Berlin, 1990.
5. M. Gielen (Ed.), Tin-Based Anti-Tumor Drugs, Springer-Verlag, Berlin, 1990.
6. M. Gielen, Coord. Chem. Rev., 1996, 151, 41-51.
7. P. Yang, M. Guo, Coord. Chem. Rev., 1999, 189, 185–186.
8. M. Gielen, M. Biesemans, D. De Vos, R. Willem, J. Inorg. Biochem., 2000, 79, 139-145.
9. M. Gielen, Appl. Organomet. Chem., 2002, 16, 481-494.
10. S.K. Hadjikakou, N. Hadjiliadis, Coord. Chem. Rev., 2009, 253, 235-249.
11. in Tin Chemistry: Fundamentals,Frontiers, and Applications; M. Gielen, A.G. Davies, K. Pannell,
E. Tiekink, Ed.: John Wiley and Sons, Wiltshire, 2008.
12. L. Nagy, A. Szorcsik, K. Kovacs, Pharm. Hungarica, 2000, 70, 53-71.
13. M. Nath, S. Pokharia, R. Yadav, Coord. Chem. Rev., 2001, 215, 99-149.
14. M. Gielen, in: NATO ASI Ser. 2, vol. 26, 1997, p. 445.
15. D. De Vos, R. Willem, M. Gielen, K.E. Van Wingerden, K. Nooter, Met. Based Drugs, 1998, 5,
179-188.
16. C. Pettinari, Main Group Met. Chem., 1999, 22, 661-692.
17. S.P. Fricker, Ed., Metal Compounds in Cancer Therapy, Chapman & Hall, London, UK, 1994, pp.
147–179.
128